With regard to our manuscripts on the commercial saliva substitute, Oralbalance®—its formula has been changed

To the editor, Previously, we published two articles in Supportive Care in Cancer on the in vitro and in vivo antibacterial effects of a commercial saliva substitute, Oralbalance® (Laclede, Inc., Rancho Dominguez, CA, USA; now GlaxoSmithKline, UK), which was a historic product for over 20 years and contributed to oral management for cancer patients with side effects such as xerostomia. The first report was entitled “An